跳至主要内容
临床试验/ACTRN12618001307291
ACTRN12618001307291招募中未知

Diagnostic accuracy and clinical utility of PSMA PET/MRI Scanning in Prostate Cancer: The SAMURAI Trial

Australian Urology Associates0 个研究点目标入组 50 人开始时间: 2018年8月3日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • (1) adult 18 years of age and above with new transperineal/transrectal biopsy diagnosed prostate cancer
  • (2) male sex
  • (3) eligible for definitive treatment with radical prostatectomy (based on age, medical co-morbidities, past history, disease progression/severity, life expectancy or other factors), as determined by the treating urologist
  • (4) eligible to undergo a Ga68 PSMA PET/CT scan as part of standard clinical care
  • (5) biopsy diagnosed cancer is intermediate risk prostate cancer or higher (greater than or equal to Gleason 3+4=7 or Grade Group 2)
  • (6) Signed, written, informed consent

排除标准

  • (1) <18 years old
  • (2) low risk prostate cancers (Less than or equal to Gleason 3+3=6 or Grade Group 1)
  • (3) previously diagnosed prostate cancers (includes treated and untreated prostate cancers)
  • (4) ineligible for definitive treatment with radical prostatectomy due to age, medical co-morbidities, past history, disease progression/severity, life expectancy or other factors as determined by the treating urologist
  • (5) contraindications to injection of Gallium 68 labelled PSMA radiotracer, magnetic resonance imaging and PET/CT

研究者

发起方
Australian Urology Associates

相似试验